- Company
- Famotidine market triples 2 years after ranitidine issue
- by Chon, Seung-Hyun Feb 9, 2022 06:09am
- The H2 receptor antagonist market had fluctuated with the ban of the ranitidine ingredient in antiulcer drugs. The gap made by the exit of ranitidine initially shrunk the market into nearly half its size. Famotidine enjoyed the most reflective benefits with its market size increasing nearly threefold after the ranitidine impurity issue. Also, ni
- Company
- Can the Antigen Rapid Test be widely used?
- by Choi-sun Feb 9, 2022 06:09am
- Although they are concerned about the transition to the COVID-19 test system, which adds the Antigen Rapid Test to the current PCR test, opinions are divided as they argue that this is only a concern. Unlike the initial virus that occurred in Wuhan two years ago, mutant viruses such as Omikron have a lot of detection in the body, so the Antigen
- Company
- EUSA Pharma establishes subsidary in Korea
- by Eo, Yun-Ho Feb 8, 2022 05:55am
- The UK-based pharmaceutical company EUSA Pharma is entering the Korean market. According to industry sources, EUSA Pharma established the Asia Pacific Regional Headquarters in Korea and launched its Korean subsidiary, EUSA Pharma Korea. EUSA Pharma is a global specialty pharmaceutical company that focuses on rare and incurable diseases
- Company
- Entresto's outpatient prescriptions exceed ₩30 billion
- by Feb 8, 2022 05:54am
- Sales of Novartis’ chronic heart failure treatment ‘Entresto’ exceeded &8361;30 billion only 5 years into its release. In the midst of drug price cuts and domestic patent challenges, Entresto is seeking greater growth this year by expanding the scope of indications and reimbursement benefits. According to the market research instituti
- Company
- Celltrion begins global P3T for its inhaled COVID-19 therapy
- by Ji Yong Jun Feb 7, 2022 05:57am
- Celltrion has begun global Phase III trials on its ‘inhaled antibody cocktail therapy’ that is in development to respond to major variants of the COVID-19 virus, such as the Omicron variant. According to the clinical trial registry ClinicalTrials.gov operated by the US National Institutes of Health (NIH), Celltrion newly registered a c
- Company
- Hugel's Letybo has been approved in France
- by Feb 7, 2022 05:57am
- Hugel announced on the 3rd that it has obtained an item license for botulinum toxin formulation Letybo from the ANSM on the 27th of last month (local time). Earlier on the 25th, Hugel received an opinion from the HMA to approve Letybo's item license. Upon receipt of the opinion, Hugel entered a national phase to enter 11 European countries, i
- Company
- Samsung BioLogics acquired ₩2.8 trillion stake in Epis
- by Ji Yong Jun Feb 7, 2022 05:57am
- Samsung Biologics will acquire all of its shares in Samsung Bioepis held by its partner Biogen. Stock purchase funds are raised through a paid-in capital increase in shareholder allocation. Samsung BioLogics announced on the 28th that it has decided to acquire all 10,341,852 shares of Samsung Bioepis held by Biogen in the U.S. for $2.3 billio
- Company
- Lorviqua can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 4, 2022 05:57am
- Preparations have begun for the prescription of Lorviqua, a third-generation ALK that seeks to register insurance benefits. According to related industries, Lorviqua of Pfizer Korea passed DC of medical institutions such as Gangnam Severance Hospital, National Cancer Center, Chung-Ang University Hospital, and Hanyang University Hospital, as w
- Company
- SK Bioscience appoints former BMS lead Pa-leun Kim as VP
- by Eo, Yun-Ho Feb 4, 2022 05:57am
- SK Bioscience is making continued efforts to strengthen the company’s capability by recruiting talents to make the leap forward and become a global vaccine company. According to industry sources, SK Bioscience appointed Pa-leun Kim (44), former Lead at Bristol-Myers Squibb Korea, as its Vice President of Communication and Government Af
- Company
- Organon Korea's Cozaar XQ will be resupplied
- by Feb 4, 2022 05:56am
- Original product for Losartan can be reproduced and prescribed in early February. Organon's HTN treatment Cozaar XQ, which was suspended due to detection of impurities above the standard last year, will be resupplied at the end of this month. Organon (CEO Kim So-eun) announced on the 27th that it will be able to re-supply Cozaar XQ from th
